StockData

Allarity Therapeutics vs CytoMed Therapeutics

ALLR and GDTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLR and GDTC compare

CytoMed Therapeutics scores higher on the StockData Score (4 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLRGDTC
Size and price
Market cap$13.4M–
Share price$0.841$0.783
Change, 1 year−28.7%−60.1%
Beta (5Y)1.46−0.42
Employees85
StockData Score
Total score14 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score12 (better)
Dividend score00
Valuation
P/B3.8×–
Growth
Revenue growth (TTM)–367%
Profitability
Net margin–−1227%
FCF margin–−1336%
Return on equity−157%−51.3% (better)
Return on invested capital−957%–
Financial health
Debt / equity5.900.06 (better)
Interest coverage−10.1×–
Current ratio1.115.17 (better)
Altman Z-score−6.65–
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield6.6%–
Shareholder yield6.6%–
Ownership
Held by institutions8.1%0.10%
Held by insiders6.3%25.9%
Insider net buying, 12 months–$729K
Short interest, % of float1.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.